JP2007522243A - Ｆｇｆシグナリングの阻害 - Google Patents

Ｆｇｆシグナリングの阻害 Download PDF

Info

Publication number
JP2007522243A
JP2007522243A JP2006553327A JP2006553327A JP2007522243A JP 2007522243 A JP2007522243 A JP 2007522243A JP 2006553327 A JP2006553327 A JP 2006553327A JP 2006553327 A JP2006553327 A JP 2006553327A JP 2007522243 A JP2007522243 A JP 2007522243A
Authority
JP
Japan
Prior art keywords
fgf
sulf1
exogenous
signaling
fgfr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006553327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007522243A5 (enExample
Inventor
エマーソン，チヤールズ・ピー，ジユニア
アル，シンビン
Original Assignee
ボストン・バイオメデイカル・リサーチ・インステイテユート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボストン・バイオメデイカル・リサーチ・インステイテユート filed Critical ボストン・バイオメデイカル・リサーチ・インステイテユート
Publication of JP2007522243A publication Critical patent/JP2007522243A/ja
Publication of JP2007522243A5 publication Critical patent/JP2007522243A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006553327A 2004-02-13 2005-02-11 Ｆｇｆシグナリングの阻害 Pending JP2007522243A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54444904P 2004-02-13 2004-02-13
PCT/US2005/004682 WO2005079390A2 (en) 2004-02-13 2005-02-11 Inhibition of fgf signaling

Publications (2)

Publication Number Publication Date
JP2007522243A true JP2007522243A (ja) 2007-08-09
JP2007522243A5 JP2007522243A5 (enExample) 2008-03-21

Family

ID=34886037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006553327A Pending JP2007522243A (ja) 2004-02-13 2005-02-11 Ｆｇｆシグナリングの阻害

Country Status (5)

Country Link
US (1) US7968527B2 (enExample)
EP (1) EP1742961A4 (enExample)
JP (1) JP2007522243A (enExample)
CA (1) CA2555417A1 (enExample)
WO (1) WO2005079390A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012075380A (ja) * 2010-10-01 2012-04-19 Soka Univ 神経細胞の製造方法及び神経細胞分化促進剤

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200914044A (en) * 2007-07-12 2009-04-01 Daiichi Sankyo Co Ltd Anti human Sulf1 antibody
WO2009011892A2 (en) * 2007-07-18 2009-01-22 Boston Biomedical Research Institute Use of suif proteins and heparan sulfate in gdnf-dependent neural innervation and protection
WO2010003023A2 (en) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1206234A4 (en) * 1999-06-03 2005-06-01 Jessie L S Au METHODS AND COMPOSITIONS FOR MODULATING PROLIFERATION AND CELL DEATH
US7129072B1 (en) * 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US20030147875A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2003012053A2 (en) * 2001-08-01 2003-02-13 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012075380A (ja) * 2010-10-01 2012-04-19 Soka Univ 神経細胞の製造方法及び神経細胞分化促進剤

Also Published As

Publication number Publication date
CA2555417A1 (en) 2005-09-01
US7968527B2 (en) 2011-06-28
EP1742961A2 (en) 2007-01-17
WO2005079390A2 (en) 2005-09-01
EP1742961A4 (en) 2009-07-15
US20050227921A1 (en) 2005-10-13
WO2005079390A3 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
Coumoul et al. Roles of FGF receptors in mammalian development and congenital diseases
Barnea et al. Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin.
Walz et al. Essential role of heparan sulfates in axon navigation and targeting in the developing visual system
Sheng et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis
Poulain et al. Heparan sulfate proteoglycans: a sugar code for vertebrate development?
Eblaghie et al. Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos
Iacovelli et al. Native group‐III metabotropic glutamate receptors are coupled to the mitogen‐activated protein kinase/phosphatidylinositol‐3‐kinase pathways
Schneider et al. The myotomal diwanka (lh3) glycosyltransferase and type XVIII collagen are critical for motor growth cone migration
Santos-Silva et al. FGF/heparin differentially regulates Schwann cell and olfactory ensheathing cell interactions with astrocytes: a role in astrocytosis
Ford‐Perriss et al. Localisation of specific heparan sulfate proteoglycans during the proliferative phase of brain development
Ohto et al. Identification of a novel nonlysosomal sulphatase expressed in the floor plate, choroid plexus and cartilage
Dabovic et al. Dual functions for LTBP in lung development: LTBP‐4 independently modulates elastogenesis and TGF‐β activity
WEKSLER et al. Differential effects of fibroblast growth factor (FGF) 9 and FGF2 on proliferation, differentiation and terminal differentiation of chondrocytic cells in vitro
Tanga et al. The PTN‐PTPRZ signal activates the AFAP1L2‐dependent PI3K‐AKT pathway for oligodendrocyte differentiation: targeted inactivation of PTPRZ activity in mice
Wu et al. Slit2 as a β-catenin/Ctnnb1-dependent retrograde signal for presynaptic differentiation
Pathre et al. PTP1B regulates neurite extension mediated by cell‐cell and cell‐matrix adhesion molecules
Bang et al. Association of focal adhesion kinase with fibronectin and paxillin is required for precartilage condensation of chick mesenchymal cells
Armendáriz et al. The diverse roles and multiple forms of focal adhesion kinase in brain
Sanchez et al. Regulation of a site-specific phosphorylation of the microtubule-associated protein 2 during the development of cultured neurons
Terajima et al. Role of glycosyltransferase 25 domain 1 in type I collagen glycosylation and molecular phenotypes
Hu et al. NDST1-dependent heparan sulfate regulates BMP signaling and internalization in lung development
Crean et al. Connective tissue growth factor/CCN2 stimulates actin disassembly through Akt/protein kinase B‐mediated phosphorylation and cytoplasmic translocation of p27Kip‐1
US7968527B2 (en) Inhibition of FGF signaling
Buczek‐Thomas et al. Heparan sulfate depletion within pulmonary fibroblasts: implications for elastogenesis and repair
Harduf et al. Sef is synexpressed with FGFs during chick embryogenesis and its expression is differentially regulated by FGFs in the developing limb

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080118

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110824

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120515